Lake Street raised the firm’s price target on OptimizeRx (OPRX) to $24 from $20 and keeps a Buy rating on the shares, telling investors that the firm was “pleased” with the company’s third consecutive strong quarter and guide. The FY26 revenue midpoint equates to growth of 13%, which compares favorably to the 11% consensus, the analyst noted.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target raised to $28 from $18 at B. Riley
- OptimizeRx price target raised to $24 from $23 at Citizens JMP
- OptimizeRx Reports Strong Q3 Growth and Raises Guidance
- OptimizeRx: Strong Financial Performance and Promising Outlook Justify Buy Rating
- OptimizeRx reports Q3 EPS 20c, consensus 5c